Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Black Diamond Therapeutics stock (BDTX)

Buy Black Diamond Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Black Diamond Therapeutics is a biotechnology business based in the US. Black Diamond Therapeutics shares (BDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Black Diamond Therapeutics employs 54 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Black Diamond Therapeutics stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Black Diamond Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BDTX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Black Diamond Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Black Diamond Therapeutics stock price (NASDAQ: BDTX)

Use our graph to track the performance of BDTX stocks over time.

Black Diamond Therapeutics shares at a glance

Information last updated 2024-07-08.
Latest market close$5.65
52-week range$1.62 - $7.66
50-day moving average $5.36
200-day moving average $3.89
Wall St. target price$12.60
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.66

Is it a good time to buy Black Diamond Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Black Diamond Therapeutics price performance over time

Historical closes compared with the close of $5.65 from 2024-07-12

1 week (2024-07-05) 26.40%
1 month (2024-06-13) -8.43%
3 months (2024-04-12) 7.82%
6 months (2024-01-12) 89.60%
1 year (2023-07-13) 15.19%
2 years (2022-07-13) 79.94%
3 years (2021-07-13) 10.87
5 years (2019-07-09) N/A

Black Diamond Therapeutics financials

Gross profit TTM $0
Return on assets TTM -38.27%
Return on equity TTM -78.81%
Profit margin 0%
Book value $1.99
Market Capitalization $251.5 million

TTM: trailing 12 months

Black Diamond Therapeutics share dividends

We're not expecting Black Diamond Therapeutics to pay a dividend over the next 12 months.

Black Diamond Therapeutics share price volatility

Over the last 12 months, Black Diamond Therapeutics's shares have ranged in value from as little as $1.62 up to $7.66. A popular way to gauge a stock's volatility is its "beta".

BDTX.US volatility(beta: 2.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Black Diamond Therapeutics's is 2.495. This would suggest that Black Diamond Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Black Diamond Therapeutics overview

Black Diamond Therapeutics, Inc. , a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc.

Frequently asked questions

What percentage of Black Diamond Therapeutics is owned by insiders or institutions?
Currently 2.337% of Black Diamond Therapeutics shares are held by insiders and 81.206% by institutions.
How many people work for Black Diamond Therapeutics?
Latest data suggests 54 work at Black Diamond Therapeutics.
When does the fiscal year end for Black Diamond Therapeutics?
Black Diamond Therapeutics's fiscal year ends in December.
Where is Black Diamond Therapeutics based?
Black Diamond Therapeutics's address is: One Main Street, Cambridge, MA, United States, 02142
What is Black Diamond Therapeutics's ISIN number?
Black Diamond Therapeutics's international securities identification number is: US09203E1055
What is Black Diamond Therapeutics's CUSIP number?
Black Diamond Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09203E105

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site